Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration
Mukai et al.
The finding, in our words
A dried blood spot method for six tyrosine kinase inhibitors was validated in 96 clinical samples. Haematocrit did not affect accuracy, stability was shown for 8-12 weeks at room temperature, and estimated plasma concentrations agreed well with measured plasma for several drugs, supporting decentralised therapeutic drug monitoring pending larger studies.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
A 2025 review maps 28 microsampling devices, from dried spots and volumetric absorptive tips to upper-arm liquid capillary collectors, and names what a laboratory must control before their results are used: the haematocrit effect in non-volumetric dried samples, interstitial fluid from finger milking, volume, haemolysis and transport stability. Regulators on both sides of the Atlantic ask for the same two things, a device the patient can use safely and a sample fit for the test.
LC-MS/MS measurement of imatinib and its active metabolite from volumetric dried blood spots collected via HemaXis DB10 and Capitainer B demonstrated analytical precision across hematocrits from 22% to 55% alongside 43-day ambient stability. Clinical evaluation across 52 paired samples showed high agreement with plasma concentrations, verifying both devices as reliable options for decentralised therapeutic drug monitoring.
Orleni et al., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (paywalled) · source ↗
The authors developed and validated an LC-MS/MS method for measuring three PARP inhibitors in both plasma and dried blood spots. They found strong agreement between the two matrices for olaparib and niraparib, suggesting DBS could support therapeutic drug monitoring for these oncology drugs in decentralised settings.
Researchers developed and validated a dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib and letrozole in breast cancer patients. Finger-prick samples showed strong correlation with plasma concentrations and remained stable at room temperature for 2.5 months, offering a decentralised approach to optimise drug dosing.
Poetto et al., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (paywalled) · source ↗